cellmid
News    Contact Us
Site Search:
home
  • About Us
    • Directors & Management
    • Scientists
    • Corporate Governance
      • Board Charter
      • Code of Conduct
      • Share Trading Policy
      • Audit Committee Charter
      • Continuous Disclosure Policy
      • Risk Management Policy
      • Performance Evaluation Process
      • Corporate Code of Conduct
    • Careers
  • Technology
    • Diagnostic
      • Human
      • Veterinary
    • Therapeutics
      • CAB101 Inflammatory Disease
      • CAMI103 Heart attack
    • Key Publications
      • Full List of Publications
    • Key Patents
  • Pipeline
    • Product Pipeline
    • Market Potential
  • New Products
    • Midkine ELISA Kit
    • Advangen International Hair Loss Products
  • Shareholder Information
    • Public Disclosure Policy
    • ASX Company Announcements
    • Financial Information & Reports
    • Share Registry Information
    • Annual General Meeting
    • Analyst Coverage
    • Share Information
  • Midkine Conference
    • 2010 Conference wrap up
      • Gallery
      • 2010 Program
    • Contact Conference Committee
cellmid-4

Novel approaches to treating important diseases


Cellmid has two therapeutic programs underway- the use of midkine protein to treat heart attack, and the use of anti-MK antibodies to treat inflammatory diseases.


Midkine for treating heart attack

Anti-midkine antibodies to treat inflammatory diseases

Also in this section
Diagnostic
Therapeutics
CAB101 Inflammatory Disease
CAMI103 Heart attack
Key Publications
Key Patents
© 2011 Cellmid Ltd. All rights reserved. ABN 69 111 304 119
Share Trading Policy | Privacy Policy | Contact Us | Site Map
Netstarter - Ecommerce Web Design, Search Marketing & Digital Strategy
{1}
##LOC[OK]##
{1}
##LOC[OK]## ##LOC[Cancel]##
{1}
##LOC[OK]## ##LOC[Cancel]##